Abionyx Pharma - Public Comps and Valuation Multiples

Abionyx Pharma Overview

About Abionyx Pharma

Abionyx Pharma is a new generation biotech company dedicated to the discovery and development of innovative therapies for patients without existing or effective treatment. The biotech assets inherited from CERENIS Therapeutics constitute a portfolio of valuable programs for the treatment of cardiovascular diseases and associated metabolic diseases such as NAFLD and NASH as well as an HDL targeted drug delivery platform in oncology, more specifically in Immuno oncology and chemotherapy.

Founded

2005

HQ

Employees

Website

abionyx.com

Sectors

Biopharmaceuticals
Drug Development & Therapeutics
BioTech

Financials

LTM Revenue $5.6M

LTM EBITDA -$12.3M

EV

$160M

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Abionyx Pharma Financials

As of August 2025, Abionyx Pharma reported last 12-month revenue of $5.6M and EBITDA of -$12.3M.

In the same period, Abionyx Pharma generated $1.6M in LTM gross profit and -$11.8M in net income.

See Abionyx Pharma valuation multiples based on analyst estimates

Abionyx Pharma P&L

In the most recent fiscal year, Abionyx Pharma reported revenue of $5.3M and EBITDA of -$4.9M.

Abionyx Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Abionyx Pharma valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	$5.6M	XXX	$5.3M	XXX	XXX	XXX
Gross Profit	$1.6M	XXX	$1.0M	XXX	XXX	XXX
Gross Margin	28%	XXX	19%	XXX	XXX	XXX
EBITDA	-$12.3M	XXX	-$4.9M	XXX	XXX	XXX
EBITDA Margin	-220%	XXX	-92%	XXX	XXX	XXX
EBIT	-$12.6M	XXX	-$5.1M	XXX	XXX	XXX
EBIT Margin	-226%	XXX	-95%	XXX	XXX	XXX
Net Profit	-$11.8M	XXX	-$5.1M	XXX	XXX	XXX
Net Margin	-211%	XXX	-96%	XXX	XXX	XXX
Net Debt	XXX	XXX	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Abionyx Pharma including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $5.6M. EBITDA for the last twelve months was -$12.3M. In the most recent fiscal year, Abionyx Pharma achieved $5.3M in revenue and -$4.9M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	$5.6M	Analyst estimates available to subscribers	$5.3M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	$1.6M	Analyst estimates available to subscribers	$1.0M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	28.4% gross margin	Analyst estimates available to subscribers	18.5% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	-$12.3M	Analyst estimates available to subscribers	-$4.9M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	-220.4% EBITDA margin	Analyst estimates available to subscribers	-92.5% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	-$12.6M	Analyst estimates available to subscribers	-$5.1M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	-225.6% EBIT margin	Analyst estimates available to subscribers	-95.0% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	-$11.8M	Analyst estimates available to subscribers	-$5.1M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	-211.5% net profit margin	Analyst estimates available to subscribers	-96.3% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	n/a	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Abionyx Pharma

This financial data table provides comprehensive performance metrics for Abionyx Pharma, a company based in France. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

Abionyx Pharma generated $5.6M in revenue over the last twelve months.
The company achieved -$12.3M in EBITDA over the last twelve months.
Gross profit for the last twelve months was $1.6M.
Net income over the last twelve months reached -$11.8M.

Fiscal Year Performance

In the most recent fiscal year, Abionyx Pharma reported $5.3M in total revenue.
Fiscal year EBITDA was -$4.9M.
The company maintained a gross profit margin of 18.5% in the most recent fiscal year.
EBITDA margin for the fiscal year was -92.5%.
Net profit margin reached -96.3% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Abionyx Pharma. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Abionyx Pharma Stock Performance

Abionyx Pharma has current market cap of EUR 137M (or $161M), and EV of EUR 137M (or $160M).

Market Cap Evolution

Abionyx Pharma Stock Data

As of September 16, 2025, Abionyx Pharma's stock price is EUR 4 (or $5).

See Abionyx Pharma trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$160M	$161M	XXX	XXX	XXX	XXX	$-0.31

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Abionyx Pharma Valuation Multiples

Abionyx Pharma's trades at 30.0x EV/Revenue multiple, and -32.5x EV/EBITDA.

See valuation multiples for Abionyx Pharma and 15K+ public comps

Abionyx Pharma Financial Valuation Multiples

As of September 16, 2025, Abionyx Pharma has market cap of $161M and EV of $160M.

Equity research analysts estimate Abionyx Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Abionyx Pharma has a P/E ratio of -13.7x.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$161M	XXX	$161M	XXX	XXX	XXX
EV (current)	$160M	XXX	$160M	XXX	XXX	XXX
EV/Revenue	28.8x	XXX	30.0x	XXX	XXX	XXX
EV/EBITDA	-13.1x	XXX	-32.5x	XXX	XXX	XXX
EV/EBIT	-12.8x	XXX	-31.6x	XXX	XXX	XXX
EV/Gross Profit	101.4x	XXX	n/a	XXX	XXX	XXX
P/E	-13.7x	XXX	-31.3x	XXX	XXX	XXX
EV/FCF	-15.9x	XXX	-36.9x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Abionyx Pharma Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Abionyx Pharma Margins & Growth Rates

Abionyx Pharma's last 12 month revenue growth is 29%

Abionyx Pharma's revenue per employee in the last FY averaged $1.1M, while opex per employee averaged $1.2M for the same period.

Abionyx Pharma's rule of 40 is -43% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Abionyx Pharma's rule of X is -148% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Abionyx Pharma and other 15K+ public comps

Abionyx Pharma Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	29%	XXX	21%	XXX	XXX	XXX
EBITDA Margin	-220%	XXX	-92%	XXX	XXX	XXX
EBITDA Growth	39%	XXX	n/a	XXX	XXX	XXX
Rule of 40	-43%	XXX	-64%	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	-148%	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	$1.1M	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$1.2M	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	42%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	114%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial